BIO-key International, Inc. (BKYI)

Nasdaq: BKYI · Services-Prepackaged Software · Holmdel, NJ · filing with the SEC since 1996

Full chart Alerts Compare

Grade2.7

◀ Past 0.7● Present 3.8▶ Future 3.0

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of BIO-key International, Inc.

Nine metrics read from its own filings, by tense

Headline grade

2.7/10

◀ Past0.725% of the headline

● Present3.835% of the headline

▶ Future3.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

0.7/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

0.0/10

Has it survived what it has been through?

32 warning events since 2017; the latest 2026-07-09.

weight 22% of this tense · 0th percentile among 230 sector filers · read for itself

From the record

BIO-key International, Inc.'s filings since 2017 show 32 warning events of 5 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2020-03-12); a notice about its exchange listing (8-K item 3.01, 15 times, the latest 2026-06-10); a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-04-22); an auditor change (8-K item 4.01, 3 times, the latest 2026-07-09); a late-report notice (Form NT 10-K or NT 10-Q, 12 times, the latest 2026-05-18) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

1.3/10

What has it actually done, year after year?

-0.7% a year over 9 filed years; profitable in 0 of 9.

weight 45% of this tense · 13th percentile among 213 sector filers · read for its customers

From the record

BIO-key International, Inc.'s 9 filed years say what it did: revenue went from $6 million in fiscal 2017 to $6 million in fiscal 2025, down 0.7% a year; it rose in 4 of 8 years; the deepest fall was 64% from fiscal 2017 to fiscal 2019; net income was positive in 0 of 9 of those years (its annual reports).

What it rests on

revenue growth over the filed span-0.7%bottom 12% of its family
the share of years revenue rosebottom 14% of its family
the share of filed years with a profitbottom 17% of its family
the deepest fall from a revenue peak64.0%bottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.3/10

How has it treated the people who own it?

SI estimate 0.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 3rd percentile among 216 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 3% of 216 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 216 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BIO-key International, Inc.'s shareholder treatment is put at 0.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 3% of 216 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.8/1035% of the headline grade · 3 of 3 filed

Financial health

as filed

3.9/10

Is it financially healthy right now?

ROE -140%: lost 140¢ per shareholder dollar. Leverage 38%: owes 38¢ per asset dollar.

weight 45% of this tense · 39th percentile among 217 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, BIO-key International, Inc. lost about 140 cents for every dollar of shareholders' money, and gross profitability: its products earned about 55 cents per dollar of everything the company owns. Leverage: it owed about 38 cents per dollar of assets, and net share issuance: its share count grew 222.7% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 40% of its family
return on equitybottom 8% of its family
gross profit against assetstop 16% of its family
the share count against the year beforebottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.2/10

How strong is its position in its industry?

bottom 12% of 218 in its family; net margin -120.6%.

weight 33% of this tense · 12th percentile among 218 sector filers · read for its customers

From the record

BIO-key International, Inc.'s standing among 218 graded names in its industry family: revenue of $6 million in fiscal 2025 ranks in the bottom 10% by size; a net margin of -120.6% ranks in the bottom 13%; revenue growth of -5.4% a year over the last 3 filed years ranks in the bottom 14% (its annual reports).

What it rests on

revenue against the family$5.9Mbottom 10% of its family
net margin-120.6%bottom 13% of its family
three-year revenue growth-5.4%bottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

7.4/10

What are the people in charge doing?

top 26% of 139 in its family for leadership; chief executive since 2006.

weight 22% of this tense · 74th percentile among 139 sector filers · read for its shareholders

From the record

BIO-key International, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Depasquale, Michael W (Chief Executive Officer, as filed), filing under that title since 2006-03-30, 20.6 years (top 2% of its family); the 4 officers and directors filing in the last fifteen months have been on the record a median of 14.8 years (top 2%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 4 people in charge now (bottom 25%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge3 in three years among 4 peoplebottom 25% of its family
the median years the people in charge have filed14.8 yearstop 2% of its family
the chief executive's years on the record20.6 yearstop 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

3.0/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

6.2/10

How much room does it have to grow?

top 38% of 216 in its family for room to expand.

weight 22% of this tense · 62nd percentile among 216 sector filers · read for itself

From the record

BIO-key International, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against no long-term debt tagged leaves 32.5% of its assets as net cash, top 20% of its family; cash from operations less capital spending is -78.8% of revenue (bottom 13%); a gross margin of 76.9% (top 32%); research spending of 44% of revenue (top 13%) (its annual report).

What it rests on

cash less debt against assets32.5%top 20% of its family
cash from operations less capital spending against revenue-78.8%bottom 13% of its family
gross margin76.9%top 32% of its family
research spending against revenue44.0%top 13% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

2.3/10

What could actually drive growth from here?

bottom 22% of 213 in its family for growth drivers.

weight 45% of this tense · 22nd percentile among 213 sector filers · read for its customers

From the record

BIO-key International, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -5.4% a year over the last three filed years against -0.7% over all 9, slowing (top 48% of its family); the newest year grew -14.3% (bottom 10%); research spending grew -7.1% a year (bottom 18%); capital spending grew -47.3% a year (bottom 10%) (its annual reports). BIO-key International, Inc. reported 3 product lines in fiscal 2025: License at $3 million (58%), Hardware at $1 million (23%), Service at $1 million (20%); 2 of 3 grew against the year before (its annual report).

What it rests on

three-year growth against the whole span-4.7 points a yeartop 48% of its family
the newest year's revenue growth-14.3%bottom 10% of its family
three-year growth of research spending-7.1%bottom 18% of its family
three-year growth of capital spending-47.3%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

2.0/10

Did its newest year beat what its own record pointed to?

bottom 20% of 194 in its family for expectations against reality.

weight 33% of this tense · 20th percentile among 194 sector filers · read for its shareholders

From the record

BIO-key International, Inc.'s newest year against its own record: revenue of $6 million in fiscal 2025 came in 13.8% below the $7 million its prior three years' pace pointed to (bottom 11% of its family); net income of $7 million against a prior three-year average of $8 million (bottom 34%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 16%) (its annual reports).

What it rests on

revenue against the prior three years' pace-13.8%bottom 11% of its family
net income against the prior three years' average+13%bottom 34% of its family
net margin against its prior average-6.7 pointsbottom 16% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BKYI · research, not advice